Welcome to our dedicated page for Grifols S A news (Ticker: GRFS), a resource for investors and traders seeking the latest updates and insights on Grifols S A stock.
News about Grifols, S.A. (GRFS) centers on its role as a global healthcare company focused on plasma-derived medicines, transfusion medicine and biopharmaceutical innovation. Founded in Barcelona in 1909 and active in more than 110 countries, Grifols regularly reports developments that matter to investors, healthcare professionals and patients.
Company news often highlights regulatory milestones for its plasma-based therapies and immunoglobulin products. Recent announcements include U.S. Food and Drug Administration (FDA) decisions on the subcutaneous immunoglobulin XEMBIFY, a fibrin sealant for surgical bleeding, and Biotest’s intravenous immunoglobulin Yimmugo. Updates on partnerships, such as collaborations with BARDA on ocular surface immunoglobulin eye drops and with The Michael J. Fox Foundation on Parkinson’s disease biomarker research, also feature prominently.
From a corporate perspective, Grifols’ news flow includes quarterly and half‑year financial results, progress on its Value Creation Plan, changes in leverage and liquidity, and dividend decisions. Filings and press releases describe revenue growth led by the Biopharma segment, trends in immunoglobulin, albumin and Alpha‑1 franchises, and performance of its Diagnostic business. Governance-related items, including amendments to Board regulations and commentary from shareholders such as Mason Capital Management, appear in communications and can influence market perception.
On this page, readers can follow earnings releases, product and pipeline updates, strategic collaborations, governance developments and other material announcements related to Grifols’ operations and capital markets activity. For investors tracking GRFS, this news stream provides context on how the company’s plasma-derived medicines, diagnostics and research initiatives evolve over time.
Grifols, S.A. filed its 2021 Annual Report on Form 20-F with the SEC on April 29, 2022. The report includes audited financial statements for the fiscal year ending December 31, 2021, reflecting Grifols' commitment to transparency for its shareholders. The Form 20-F is accessible on Grifols' website and the SEC's site. Shareholders can request a hard copy of the report free of charge. Grifols has an economic impact of €7,700 million and is a major player in the plasma industry with over 23,000 employees in 30+ countries.
Grifols has successfully acquired 100% of Tiancheng Pharmaceutical Holdings AG, providing a 96.20% voting rights control over Biotest AG. The transaction, valued at approximately EUR 1,600 million, enhances Grifols' capabilities in plasma therapies, expanding its network to 87 plasma centers. This strategic acquisition aims to accelerate growth, boost revenues, and improve profitability starting in 2024 through new product launches. Regulatory approvals were secured from authorities in Turkey, Germany, and Spain, underlining the transaction's significance.
Grifols (GRFS) has partnered with Feeding America to combat hunger in the U.S. through its Box Out Hunger initiative. In March, Grifols aims to collect over 1 million pounds of nonperishable food by collaborating with local businesses and community organizations. Last year, the program gathered 800,000 pounds. Employees and donors can also contribute monetarily, with the J.A. Grifols Foundation matching donations. This marks the first collaboration with Feeding America, enhancing Grifols' commitment to social responsibility while supporting the urgent need for plasma donations amidst the COVID-19 pandemic.
Grifols (NASDAQ: GRFS) announced a collaboration with Endpoint Health to develop and commercialize Antithrombin III (AT-III) therapy targeting Sepsis. Grifols will be the exclusive supplier of AT-III, contributing $25 million to support clinical development. An Investigational New Drug (IND) application will be submitted for a Phase II trial later this year. Endpoint Health will utilize its AI technology to identify patients likely to benefit from AT-III. The collaboration aims to improve patient outcomes and strengthen Grifols' plasma economics.
Grifols, a leader in plasma-derived medicines, announced its PharmacyKeeper Verification software has been named the No. 1 Category Leader in IV Workflow Management by KLAS Research for the sixth consecutive year. This accolade underscores Grifols' commitment to enhancing patient care through technology. PharmacyKeeper is part of Grifols' IV compounding solutions, which aim to reduce medication errors, while the Best in KLAS report emphasizes user feedback to recognize top healthcare technology vendors.
Grifols has acquired its first plasma donation center in Canada, purchasing Prometic Plasma Resources Inc's Winnipeg site from Kedrion for USD 4 million. This acquisition supports Grifols’ strategy to enhance the availability of lifesaving plasma medicines in Canada, complementing its existing production capabilities in the country. With an annual capacity of 1.5 million liters at its plasma fractionation plant, Grifols aims to leverage its extensive experience in Canadian plasma. The company remains committed to ensuring the quality and safety standards of plasma usage for patients.
Grifols has opened its 300th plasma donor center in Worcester, Massachusetts, marking a significant milestone for the company. This facility, part of the largest global network of plasma donor centers, aims to address the urgent need for plasma donations, which have been declining due to the COVID-19 pandemic. With over 350 centers worldwide, Grifols plans to operate 370 centers by the end of 2021. Plasma is crucial for creating lifesaving therapies for patients with chronic and rare diseases.
Grifols has launched its new ALBUTEIN FlexBag™, offering albumin in 5% and 25% concentrations, catering specifically to U.S. hospitals and pharmacies. This innovation features an easy-to-use port, minimizing bubble accumulation and needle stick risks. The FDA approved the 5% and 25% concentrations earlier in 2021, with a focus on sustainability, reducing the carbon footprint by 40% during manufacturing. This launch underscores Grifols' commitment to research and innovation, expanding its plasma-derived medicine portfolio to enhance patient care.
Grifols has launched HyperHEP B, a new formulation of hepatitis B immune globulin, approved by the FDA in December 2020, specifically for postexposure prophylaxis against hepatitis B. The product, utilizing a unique purification process, aims to enhance safety standards and reduce procoagulant activity. HyperHEP B is expected to serve approximately 800,000 to 1.4 million infected individuals in the U.S., with three different presentation sizes available. Grifols' ongoing commitment includes donating six million international units to underserved countries.
Grifols has announced the opening of the first AMBAR® Center in Barcelona, collaborating with Ace Alzheimer Center Barcelona. This center aims to collect real-world data from the AMBAR® clinical program, which uses periodic plasma exchange to slow cognitive and functional decline in Alzheimer's patients. The partnership aims to enhance the treatment and management of Alzheimer's with plans for future centers in the EU, U.S., and China. Over 35 million people globally suffer from Alzheimer's, emphasizing the significance of this innovation.